TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Regeneron Pharmaceuticals, Inc.
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

Regeneron announced positive Phase 2 trial results for two novel factor XI antibodies (REGN7508Cat and REGN9933A2) that demonstrate robust anti-clotting effects with minimal bleeding risk in patients undergoing total knee replacement surgery.

Insights
GSpC   neutral

Serving as joint sponsor, overall coordinator, and global coordinator for the IPO, indicating a standard professional engagement


REGN   positive

Successfully demonstrated promising Phase 2 trial results for novel antibodies with potential to improve anticoagulation therapy, showing reduced venous thromboembolism rates and minimal bleeding risks